PT1385512E - Utilizacao de derivados de piridoindolona para preparacao de medicamentos anticancerigenos - Google Patents

Utilizacao de derivados de piridoindolona para preparacao de medicamentos anticancerigenos

Info

Publication number
PT1385512E
PT1385512E PT02732841T PT02732841T PT1385512E PT 1385512 E PT1385512 E PT 1385512E PT 02732841 T PT02732841 T PT 02732841T PT 02732841 T PT02732841 T PT 02732841T PT 1385512 E PT1385512 E PT 1385512E
Authority
PT
Portugal
Prior art keywords
pyridindolone
anticancerigene
medicines
derivatives
preparation
Prior art date
Application number
PT02732841T
Other languages
English (en)
Portuguese (pt)
Inventor
Bernard Bourrie
Pierre Casellas
Derocq Jean-Marie
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PT1385512E publication Critical patent/PT1385512E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT02732841T 2001-04-27 2002-04-26 Utilizacao de derivados de piridoindolona para preparacao de medicamentos anticancerigenos PT1385512E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (1)

Publication Number Publication Date
PT1385512E true PT1385512E (pt) 2006-05-31

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02732841T PT1385512E (pt) 2001-04-27 2002-04-26 Utilizacao de derivados de piridoindolona para preparacao de medicamentos anticancerigenos
PT02735502T PT1385513E (pt) 2001-04-27 2002-04-26 Associações farmacêuticas à base de derivados de piridoindolona e agentes anticancerígenos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT02735502T PT1385513E (pt) 2001-04-27 2002-04-26 Associações farmacêuticas à base de derivados de piridoindolona e agentes anticancerígenos

Country Status (33)

Country Link
US (3) US6967203B2 (enExample)
EP (2) EP1385512B1 (enExample)
JP (2) JP2004531538A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE314070T1 (enExample)
BG (2) BG108260A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2444334A1 (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ295224B6 (enExample)
DE (2) DE60214533T2 (enExample)
DK (2) DK1385513T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2271264T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400745A2 (enExample)
IL (4) IL158266A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034785L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385512E (enExample)
RS (2) RS50791B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087575A1 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
JPH10501686A (ja) * 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのｄｎａのａａｖ仲介送達
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
CA2326319A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CZ20032909A3 (en) 2004-06-16
YU83903A (sh) 2006-08-17
CA2444334A1 (fr) 2002-11-07
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
ES2271264T3 (es) 2007-04-16
WO2002087574A3 (fr) 2003-02-13
EE200300465A (et) 2003-12-15
US20050272760A1 (en) 2005-12-08
IL158266A (en) 2009-09-01
RU2292888C2 (ru) 2007-02-10
NZ528671A (en) 2004-06-25
US7160895B2 (en) 2007-01-09
EA005930B1 (ru) 2005-08-25
NO20034787L (no) 2003-12-23
DE60214533D1 (de) 2006-10-19
EA200301062A1 (ru) 2004-04-29
IL158312A (en) 2009-09-01
PT1385513E (pt) 2007-01-31
CZ295224B6 (cs) 2005-06-15
DE60208365T2 (de) 2006-09-07
YU83403A (sh) 2006-08-17
JP2004531538A (ja) 2004-10-14
AR034313A1 (es) 2004-02-18
SK13242003A3 (sk) 2004-03-02
HK1060066A1 (en) 2004-07-30
IS6984A (is) 2003-10-09
NO20034787D0 (no) 2003-10-24
MXPA03009639A (es) 2004-06-30
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
KR20040015138A (ko) 2004-02-18
DK1385512T3 (da) 2006-05-22
EP1385513B1 (fr) 2006-09-06
DE60214533T2 (de) 2007-06-21
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
CN1505511A (zh) 2004-06-16
DK1385513T3 (da) 2007-01-15
PL366910A1 (en) 2005-02-07
CA2443012C (fr) 2009-07-28
HK1059895A1 (en) 2004-07-23
CZ20032910A3 (en) 2004-07-14
NO20034785D0 (no) 2003-10-24
CZ299465B6 (cs) 2008-08-06
KR100847413B1 (ko) 2008-07-18
CA2443012A1 (en) 2002-11-07
UA74876C2 (en) 2006-02-15
HUP0400745A2 (hu) 2004-08-30
RS50791B (sr) 2010-08-31
EP1385512B1 (fr) 2005-12-28
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
FR2823975A1 (fr) 2002-10-31
RU2003130376A (ru) 2005-04-10
PL366916A1 (en) 2005-02-07
CN1240382C (zh) 2006-02-08
EE200300466A (et) 2003-12-15
ZA200307785B (en) 2004-10-06
BR0209138A (pt) 2004-06-08
US6967203B2 (en) 2005-11-22
US7524857B2 (en) 2009-04-28
JP2004528343A (ja) 2004-09-16
IS2441B (is) 2008-11-15
ATE314070T1 (de) 2006-01-15
IL158312A0 (en) 2004-05-12
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
EP1385513A1 (fr) 2004-02-04
RS50790B (sr) 2010-08-31
SK13252003A3 (sk) 2004-03-02
WO2002087575A1 (fr) 2002-11-07
US20040122027A1 (en) 2004-06-24
CN1505510A (zh) 2004-06-16
US20040122036A1 (en) 2004-06-24
BG108260A (bg) 2004-12-30
CY1105813T1 (el) 2011-02-02
HUP0400744A2 (hu) 2004-06-28
ES2254683T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
NO20033384D0 (no) Farmasöytisk formulering
NO20033785D0 (no) Farmasöytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
FI20011478A0 (fi) Farmaseuttinen koostumus
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
EE05020B1 (et) Glburiidi ravimkoostis
NO20035627D0 (no) Farmasöytisk formulering
NO20035315D0 (no) Farmasöytiske kombinasjoner
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
SI1475379T1 (sl) Uporaba derivatov skopinskega estra za pripravo zdravil
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
PT1385512E (pt) Utilizacao de derivados de piridoindolona para preparacao de medicamentos anticancerigenos
AR028400A1 (es) Procedimiento para la preparacion de compuestos halogenados de hidroxidifenilo
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
AR028111A1 (es) Procedimiento para la produccion de isocianatos
EP1413314A4 (en) MEDICAL COMPOSITIONS
NO20041236L (no) Farmasoytisk formulering
ITMI20012131A0 (it) Procedimento per la preparazione di alo-benzonitrili
ES1049731Y (es) Dispositivo para la administracion de farmacos.
SE0102957D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation